PRAME antibody (AA 321-509)

Catalog No. ABIN1589821

Product Details anti-PRAME Antibody

Target: PRAME (Preferentially Expressed Antigen in Melanoma (PRAME))

Binding Specificity: AA 321-509

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This PRAME antibody is un-conjugated

Application: Western Blotting (WB)

Purpose: PRAME antibody

Specificity: Recombinant human PRAME (Met321-Asn509)

Immunogen: Recombinant human PRAME (Met321-Asn509)

Isotype: IgG

Application Details

Application Notes: Western Blot: Use 1-5 μg/mL

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/mL.

Buffer: PBS

Handling Advice: Centrifuge vial prior to opening.

Storage: 4 °C,-20 °C

Storage Comment: The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots.

Expiry Date: 24 months

Target Details for PRAME

Target: PRAME (Preferentially Expressed Antigen in Melanoma (PRAME))

Alternative Name: PRAME (PRAME Products)

Synonyms: PRAME antibody, CT130 antibody, MAPE antibody, OIP-4 antibody, OIP4 antibody, 4930534P07Rik antibody, preferentially expressed antigen in melanoma antibody, PRAME antibody, Prame antibody

Background: Melanoma antigen preferentially expressed in tumors, Opa-interacting protein 4, MAPE, OIP4,PRAME/MAPE/OIP4 is a germinal tissue-specific gene that is also expressed at high levels in haematological malignancies and solid tumors. The physiological functions of PRAME in normal and tumor cells are unknown, although a role in the regulation of retinoic acid signaling has been proposed. Sequence homology and structural predictions suggest that PRAME is related to the Leucine-rich repeat (LRR) family of proteins, which have diverse functions. PRAME, or ""preferentially expressed antigen in melanoma"", was originally identified as a gene encoding a HLA-A24 restricted antigenic peptide presented to autologous tumor-specific cytotoxic T lymphocytes derived from a patient with melanoma. PRAME is synonymous with MAPE (melanoma antigen preferentially expressed in tumors) and OIP4 (OPA-interacting protein 4), and its expression profile defines it as a cancer-testis antigen. Cancer-testis antigens (CTAs) are encoded by non-mutated genes expressed at high levels in germinal tissues and tumors, but which are absent from or detected at low levels in other tissues. PRAME may be somewhat different to other cancer-testis antigens in that it shows some expression in normal tissues such as ovary, adrenal, placenta and endometrium. The C-terminus of human PRAME (amino acids 453-509) was also identified to bind Neisseria gonorrhoeae opacity factors, in this case the OPA-P protein. Thus PRAME is also known as OIP4 (OPA interacting protein),

Gene ID: 23532

NCBI Accession: NM_006115, NP_006106

UniProt: P78395

Pathways: Retinoic Acid Receptor Signaling Pathway, Nuclear Hormone Receptor Binding